Posted by AGORACOM-JC
at 5:31 PM on Wednesday, February 23rd, 2022
If there is one thing we know about governments (local, state, Federal) it is they have lots of responsibility AND are hugely inefficient. Who hasn’t had a bad experience with government departments a few times in their life? Much of it stemming from antiquated software systems that often fail to keep track of critical information.
HealthSpace “is empowering governments efficiency” which in turn has powered them to become an industry leading technology company providing both enterprise and mobile internet-based applications to over 500 state, local and federal government organizations across North America.
More Than Just Lip Service
RECORD REVENUE:
● $1.038M Q ending Sept 30, 2021. Up 66% vs 2021
● ~$2.8M in 9 months revenue. Up 85% vs same period in prior year
● $US 25M+ Sales Pipeline
MAJOR CONTRACTS:
● Riverside County California (New) $1.3M
● Sacramento County California $1.55M
● Fraser Health, BC $1.01M
● Larimer County, Colorado and Ogle County, Illinois $517,400
● Anaheim Fire and Rescue Department $193,990
● $340,000 in New Contracts with Health Canada, Johnson County, MO, Shelby County, TN and KFLA in Ontario
FINANCINGS:
● $5.2 Million financings recently closed
On today’s interview we’ll be discussing, US$1.3 Million Contract with Riverside County, California. This contract will add an average of US$148,000 in Annual Recurring Revenue not including future revenue anticipated as part of HSPay.
What did HealthSpace CEO, Silas Garrison have to say?
“I am pleased to announce our first contract of 2022. Fittingly, it is in California ; a market that we have served well and continues to look to us during a period of technology transition for environmental health departments across the state. We appreciate the trust agencies all around California are placing in HealthSpace, and we look forward to much growth in the state, as well as the rest of the county, as we progress through 2022.”
Sit back, relax and watch this powerful interview.
Posted by AGORACOM-JC
at 8:28 AM on Friday, February 18th, 2022
*AGORACOM Engagement Metrics Beat Benchmarks By 364% *AGORACOM Cashless Marketing Program Is 100% Compliant With TSXV, CSE and NEO
We are very proud to announce AGORACOM achieved another major milestone for the period December 31, 2021, when we surpassed 710 Million page views (81% AGORACOM / 19% Twitter) from 8.8 Million investors that visited 63.3 Million timesover the last 13 years.
These milestones are significant because they continue to demonstrate that AGORACOM is the primary home for serious small cap investors that want to discover their next great small cap investment. We owe much of this success to the following 2 major factors:
QUALITY OVER QUANTITY – Unlike small cap sites and major platforms that struggle with spam, profanity and overall nonsense, AGORACOM has implemented and strictly enforces it’s 6 Rules Of Use that create robust but civilized debate and discussion.
FOCUS. NOTHING BUT SMALL CAP – Despite the fact we are all in the finance industry, we don’t talk about macro finance, large cap or general economic news. Investors come to AGORACOM for just one thing – great small cap content .. and they don’t hesitate to show their love for us. AGORACOM ENGAGEMENT SHATTERS FINANCE BENCHMARKS BY 364%
AGORACOM small cap investors don’t just flip through pages, they invest a significant amount of time reading, studying and researching our small cap stocks like yours. …. And they do it far more than everywhere else. Here are the numbers:
PAGES READ PER VISIT > 364% HIGHER THAN INDUSTRY STANDARD
In a recent survey of 357 finance sites, LittleData determined the average number of pages read per visit was 2.0. The average number of pages read on AGORACOM are 9.28, which is 364% higher than the benchmark.
Moreover, when it came to the best 10% of all finance sites, AGORACOM has them beat hands down as well, with LittleData determining anything greater than 4.1 pages per visit represents the best 10% of all Finance sites. With AGORACOM registering 9.67 pages per visit for a 136% beat, it is fair to say AGORACOM is in elite status for engagement.
TIME SPENT PER VISIT > 161% HIGHER THAN INDUSTRY STANDARD
The average visitor to AGORACOM stays on the site for an average of 8 mins 23 secs. To put this into perspective, The Contentsquare Digital Experience Benchmark Report determined an average visit to financial services sites of 3 mins 13 secs, placing AGORACOM engagement 161% higher. Here are some comparables against some of the world’s biggest finance sites:
AGORACOM 8 mins 23 secs Wall Street Journal 3 mins 18 secs Marketwatch 5 mins 47 secs Motley Fool 1 mins 50 secs FOX Business 3 mins 39 secs Investing.com 5 mins 53 secs
HOW DOES AGORACOM CREATE INDUSTRY LEADING ENGAGEMENT?
The fight for investor attention is stronger than ever. Within the small cap industry investors are inundated with mountains of information from email to social media.
Moreover, the small cap industry is now facing stiff new competition for investor attention from the fast rising Web3 world of Cryptocurrencies, NFTs and Blockchains.
It’s enough to make both investors and issuers dizzy.
AGORACOM overcomes this challenge and wins the battle for investor attention by going the extra mile to create great content. While most firms communicate via “lazy linking” AGORACOM Founder and former lawyer George Tsiolis relies on his communications training to make sure the account management team delivers the following winning variety of content:
FORM – Blogs, Posts, Tweets, Comments, Videos, Audio, Graphics and GIFs
LENGTH – Ultra Long, Long, Medium, Short and Micro
PLATFORMS – YouTube, Twitter, LinkedIn, Facebook, Instagram, Spotify, Search, TikToK (yeah but no dancing!) … and of course our very own AGORACOM.com
Watch this concise but powerful 60-second video to get a great glimpse of our industry leading content machine. This unmatched variety in the form, length and distribution of our content removes all the noise for investors while providing clients with a complete digital marketing solution.
ZERO $ … AGORACOM CASHLESS AND 100% COMPLIANT PROGRAM
As a small cap company, your cash is invaluable and shouldn’t be used for anything other than operations and growth. You’ll be happy to know The AGORACOM Cashless, Shares For Services Program is fully compliant with the TSX Venture, CSE and NEO Exchanges. As such, it is considered the friendliest comp structure in the entire industry and can be summarized as follows:
Shares are issued in 5 X $20,000 installments over the twelve month term.
-Start Date -End Of Q1 -End Of Q2 -End Of Q3 -End Of Q4
-The number of shares issued is determined by the share price at each date. As the issuer share price goes higher, the number of shares issued to AGORACOM decreases.
-Each issuance comes with customary 4-month hold periods. As such, AGORACOM is a shareholder for at least 16 months (Q4 + 4 Months)
-Structure means AGORACOM becomes a long-term shareholder that is completely aligned with the Company
-$0 Cash + the full firepower of AGORACOM
CONCLUSION
Massive audience + industry leading engagement + industry leading content + $0 cash, 100% compliant shares for services
We are pleased to announce we have been selected by the Ketamine Research Foundation (KRF) to host a phase II clinical trial investigating ketamine-assisted psychotherapy (KAP) for adults with life-threatening illness (Conscious Dying/Conscious Living Trial).
“This study is an important addition to the clinical care and research opportunities for patients within the Psychedelic Palliative Care program that we are building at Novamind,” said Dr. Paul Thielking, Chief Scientific Officer and Principal Investigator at Novamind’s Murray research site. “I’ve worked with this population for most of my career and, unfortunately, I’ve sometimes felt limited in what I can offer my patients to ease their emotional distress. The findings will contribute to the evidence for using KAP with patients who have a life-threatening illness and offer new insights into alternative treatments.”
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore the many facets of anger. They discuss the following: how conditioning affects how we process emotions like anger, the corrective emotional experience afforded by MDMA-assisted psychotherapy and much more.
The Huntsman Cancer Institute in Salt Lake City, Utah is investigating group psilocybin therapy as a treatment for anxiety and depression in cancer patients. Dr. Paul Thielking, who serves as the study’s lead therapist, explains that even just one dose of psilocybin could entirely shift the patient’s perspective on their illness and situation. Even more remarkable? The effects of those experiences seem to last—in some case, more than four years.
Microdosing. Does it work? Amidst increased buzz around the benefits of the practice, research continues to tackle this difficult question. This week, a new double-blind study revealed that microdosing with LSD produces “negligible changes in mood and cognition”, and there has been no research on the efficacy for people suffering from anxiety and depression. Check out National Geographic’s microdosing feature to learn more about current research, perspectives, and remaining questions.
Posted by AGORACOM
at 12:21 PM on Thursday, February 3rd, 2022
TSX listed Candente Copper owns Canariaco Norte, a large, economic copper deposit in Peru that continues to advance technically and economically toward a sale or production decision. A 2022 Preliminary Economic Assessment (“PEA”) is nearing completion that will advance it further toward development
Now it has a sister deposit, Canariaco Sur located 2km away that could help advance developments much quicker.
Canariaco Sur contains 2.2 billion pounds of copper and 1.2 million ounces of gold in an inferred resource calculated with only 15 holes, demonstrating a considerable amount of metal. Sur contains higher levels of gold and molybdenum than Cañariaco Norte, minimal arsenic levels and mineralization that starts at surface. Cañariaco Sur has the potential to add significant value to the resources at Cañariaco Norte, 2km to the northeast.
Cañariaco Norte is a 100% owned pre-feasibility-stage porphyry copper deposit containing 7.5B pounds Measured and Indicated and can be mined for 22 years once in production. Oh, and Canariaco Norte is in the lowest quartile of production costs for projects waiting to be developed at around 0.98c per pound of copper. If that doesn’t have your attention, the third party validation will, look at these partners supporting Candente in 4 research papers comparing various global copper projects in the last 4 years as it now moves 2 deposits toward development:
RFC Ambrian: Cañariaco Norte in top 10 of 23 projects with potential to involve third party M&A (December 2021) Haywood: Cañariaco Norte is one of 18 assets selected as likely to be considered by majors looking to acquire (December 2021) Deutsche Bank: Cañariaco Norte identified as one of 3 projects required to meet the upcoming copper supply-demand gap (February 2021) Goldman Sachs: Cañariaco Norte identified with incentive copper price in the lowest quartile of the top 84 copper projects worldwide (October 2018)
Canariaco Norte is a deposit itching to become a mine and Candente continues to advance the project forward with studies evaluating various methodologies to reduce CAPEX with multiple scenarios that support developing Canariaco closer to a production scenario.
With the price of copper firmly above $4 dollars, the economics supporting Canariaco going into production only gets stronger, and now Canariaco has a sister deposit helping to expedite matters. Watch this great interview with Candente CEO Joanne Freeze as walks through Canariaco Sur and the exciting new developments aiding the development of 2 exciting copper porphyry deposits.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore the topic of depression and whether or not psychedelic medicine can help treat it. They discuss the following: depression and suicidal ideation, ketamine treatment for depression, the qualities to look for in a professional helper, and much more.
Chief Medical Officer, Dr. Reid Robison sits down with The Dales Report to discuss his involvement in a number of studies involving ketamine and other drugs that target the same mechanisms. Many of the questions he’s asked along the way focus on safety considerations and optimal conditions for treatment.
While classic psychedelics work towards FDA approval, global drug developers are moving beyond traditional plant medicines to focus their attention on the creation of novel “precision psychedelics”, compounds with shorter trips, less side effects, and, in some cases, no hallucinogenic component. Researchers are hopeful their efforts will increase access and scalability of psychedelic treatment. “I try to think of my mom,” one COMPASS chemist explains. “If she had to have this medication, what would I want for her as an ideal compound and ideal experience?”
100,000 overdose deaths occurred in the U.S. between April 2020 and April 2021. Despite the steady rise of overdose deaths in the U.S. over the last two decades, the latest data raises an alarm about the increased need for substance use disorder prevention and treatment. Novamind recently announced plans to develop an innovative substance use disorder program. We’re also hosting a clinical trial for ketamine-assisted psychotherapy + mindfulness for opioid use disorder. Read about it here.
We are pleased to announce that, further to our press release dated December 23, 2021, we have closed our acquisition of Arizona-based Foundations for Change, Inc., a mental health practice specialized in ketamine-assisted psychotherapy.
“We’re thrilled to welcome the team from Foundations,” commented Novamind CEO and Director, Yaron Conforti. “The Acquisition is an exciting opportunity for Novamind to expand the reach of our clinic network, bringing our model for innovative mental healthcare to a new market in Arizona.”
With the closing of the Acquisition, Foundations founder Jeff Edelman, MSN, APRN, PMHNP-BC, PMHCNS-BC, assumes the role of Medical Director at the Peoria and Phoenix clinic locations.
Mr. Edelman commented: “Joining Novamind is the right fit for our team and aligns with our mission to provide innovative and compassionate mental healthcare. I would like to thank our patients, partners and community for their ongoing support over the years. We look forward to integrating our team and operations with Novamind and benefiting from its deep expertise and infrastructure as we continue to serve a growing patient population.”
We are pleased to announce our participation in Citi’s Psychedelic Drug Video Call Series to be held virtually on January 25, 2022.
Neena Bitritto-Garg, Vice President Research Analyst, Biotech, at Citi, will host Novamind’s Chief Executive Officer, Yaron Conforti and Chief Medical Officer, Reid Robison, MD, MBA, for a fireside chat at 10:00 AM ET.
“Novamind has an established track record as a leader in commercializing psychedelic medicine and other innovative mental health therapies through a growing network of clinics and hosting an exciting pipeline of clinical trials for major drug developers,” said Mr. Conforti. “I look forward to introducing Citi’s clients to Novamind and expanding our relationships with a global base of institutional investors.”
To register for the call, please contact your Citi representative directly.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore whether or not psychedelic medicine can change your personality. They discuss the following: alter states for altered traits, “ego” and how psychedelic medicine can lead to personality changes, and much more.
In the latest issue of Mental Health Weekly, Chief Medical Officer Dr. Reid Robison discusses the benefits and barriers of psychedelic treatment and weighs in on the progress of MDMA & psilocybin research and legislative activities in the US.
Perceptions on the potential of psilocybin therapy are shifting in the medical community, according to a recent COMPASS Pathways-sponsored survey. “Severe mental illnesses, such as treatment-resistant depression, have affected too many people in society for too long. Physicians are looking for new approaches to accelerate the healing process, particularly for patients for whom current therapies have failed.”
A new study by Jay Nair and colleagues from MAPS PBC tries to answer the question of how psychedelic substances will be produced. This is an important step and still, “Many open questions remain about the legal framework that needs to materialize, who will distribute the medicines, and who will be qualified to provide the treatment.” Dr. Robison sat down with Mental Health Weekly for similar conversation.
Lucid News’ Itzhak Beery explores the role of shamanism in Western medicine. “Some psychotherapists feel pressured to offer this type of healing to their clients, who have heard about these magical treatments and hope for a short cut to relief. Most facilitators do not acknowledge the element of spirit or the unseen world.” We’ve also explored this question (and more) in a previous episode of the Psychedelic Frontiers Podcast. Listen to it again here.
We are pleased to unveil our clinic design concept to accommodate the unique requirements of psychedelic-assisted psychotherapy. The design concept will launch first in Novamind’s Park City, Utah location, and later across Novamind’s de novo clinics. Select design elements and principles will be integrated within existing clinic locations.
Inclusive and welcoming, the design concept enhances the patient experience at Novamind clinics, prioritizing patient safety and privacy, and utilizing evidence-based therapeutic elements to optimize patient care, including:
Biophilic designs that mimic nature and emphasize light interplay and neutral colour theory
Walking paths designed to minimize disruption and traffic across the clinic, creating a sense of privacy and tranquility
Curved treatment spaces, representing the protective space of cocoons, to facilitate the more sedentary experience of ketamine treatment
Larger treatment rooms to accommodate group therapy programs and support movement and more active patient behaviours associated with MDMA, psilocybin and other psychedelic medicines when approved by the FDA
To create the Design Concept, Novamind contracted DesignAgency, an internationally recognized interior design firm with clients that include the Four Seasons Hotels, MGM Resorts, Momofuku restaurants, Soho House and others. DesignAgency worked closely with Novamind’s clinical team to incorporate a host of therapeutic considerations into the design blueprint to achieve optimal patient experiences.
“We collaborated with Novamind’s clinical team and understood the importance of ‘set and setting’ in psychedelic medicine,” said Matt Davis, Co-Founder and Principal at DesignAgency. “The goal was to create spaces that allow patients to have a holistic experience and signal hope and healing well before they walk through the door.”
Dr. Reid Robison, Chief Medical Officer at Novamind, commented: “This new concept, combined with Novamind’s standard operating procedures, creates the most welcoming and effective healing environment possible. We wanted our clinics to be comforting, inviting and calming. With guidance from the DesignAgency team, we now have the blueprint to create spaces that elevate our patients’ healing experience.”
To see renderings of the Design Concept, click here.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Dr. Amy de la Garza. Amy is the Substance Use Disorder Program Director at Novamind and the Medical Director of the Salt Lake City clinic. Amy is a board-certified family practice physician who for the last 10 years has been providing specialized integrative healthcare for behavioral health, substance use, and a variety of other conditions.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss qualities and skills they think are essential for therapists who provide psychedelic-assisted psychotherapy.
We’re celebrating 8 months of the podcast with a GIVEAWAY on Instagram! Enter to win a sweatshirt featuring the audio waves from a fan-favorite episode of Psychedelic Therapy Frontiers.
This is big news for Canada overall. “Long-awaited amendments to Health Canada’s Special Access Program have finally been made, potentially opening the door to less onerous access to the medical access of psychedelics like psilocybin and MDMA for patients in need.” Our mission has always been to increase access to these life-changing therapies and drugs in safe and regulated settings. We celebrate this news and will continue to do our part to bring psychedelic medicine to as many people in need as possible.
PSYCH covers the year in psychedelic healthcare. “2021 was a seminal year for psychedelic medicine, with data released from groundbreaking clinical trials harnessing MDMA and psilocybin.” 2021 was special, but we can’t wait to work on making 2022 even more impactful for people around the world. For more great psychedelic content from PSYCH, download the third edition of the Psychedelics as Medicine Report here.
Dr. Reid Robison and the team at Novamind have spent years providing ketamine-assisted psychotherapy and seeing the positive benefits firsthand. It’s changed the lives of thousands of our patients. We recently published a story about how ketamine helped a mother struggling with severe depression and a struggling marriage. You can read it here. Seeing the results of this systematic review by the University of Exeter is both exciting and validating. “Ketamine therapy has a swift short-term effect on reducing symptoms of depression and suicidal thoughts, according to a review of all the available evidence.”
Posted by AGORACOM-JC
at 1:40 PM on Thursday, January 6th, 2022
Valeo Pharma is already a successful, revenue-generating, small-cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small-cap pharma companies.
The company released stellar a Q3 with the following highlights:
Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
Record 9 months revenues at $10.2 million , up 94%
Approved by Health Canada for immune support, is now available for sale in approximately 300 stores under the Loblaw’s banners including:
Loblaws
Dominion,
Zehrs,
Fortinio’s,
Your Independent Grocer and Superstore
Steve Saviuk , CEO commented,
We are very pleased to announce that Hesperco is now available in over 300 Loblaw banner stores. The immune support properties of hesperidin, the sole medicinal ingredient contained in Hesperco capsules, has been well documented in numerous scientific publications. We are also encouraged by the results of the Hesperidin Covid-19 clinical trial which has recently been submitted for publication. The study concluded that hesperidin could have beneficial effects and may help reduce certain Covid-19 symptoms. The publication further suggested that earlier treatment of longer duration and/or higher dosage should be studied.”
Posted by AGORACOM-JC
at 6:11 PM on Wednesday, January 5th, 2022
The genesis of Liquid Avatar Technologies is a global blockchain & personal identity solutions company specializing in empowering individuals to manage, control and generate value from their biometrically-verified digital Identity, which also provides businesses and governments the ability to easily integrate digital wallets and digital identity solutions through its Liquid Avatar platform (www.liquidavatar.com)
And if the story ended there, that would be more than enough to build a company on.
However, as the digital universe has continued to expand, there is an ever-increasing need to verify online identity as governments and enterprises around the world prepare for the shift. For example:
In early 2021 Google announced a major shift away from precision-targeting of ads based on everything you do on the internet
The Ontario Government released its Digital Strategy, with key themes including the launch of Digital ID credentials.
“Ontario is one of the first jurisdictions in North America to announce that it will issue and enable digital credentials – and it has been a great experience working with the government on this both directly and through our role in membership organizations like the Trust Over IP Foundation,
As a result, the Liquid Avatar Verifiable Credentials Ecosystem (LAVCE) is being built to support all participants in a digital credential ecosystem. Almost immediately, Liquid Avatar announced a big win here by partnering with the Ontario Convenience Stores Association (OCSA) To Provide Digital Age-Verification Solutions To Over 8,000 Stores.
Again, if the story ended there, Liquid Avatar would have the makings of a potentially massive tech company.
But with the rise of NFTs and the Metaverse, both of which strongly rely on digital identity, the Company continued to expand its core digital identity technology into these areas and registered major successes, including $1,000,000 in Preliminary Gross Revenues for its Aftermath Islands Metaverse.
“Our in-market businesses continued to perform above expectations for Q4, and we remain optimistic, while cautious, as these are still early days in the Company’s transformation to an active revenue organization. We have started to witness online acceptance of digital identity programs, which are at the core of all our solutions, and both avatar and metaverse activities are gaining traction, creating opportunities for early revenue there, as the industry embraces the future of Web 3.0. Our goal is to continue to create value for all our stakeholders.”
If you believe in the future of Web3 (blockchain, crypto, tokens, NFTs and the Metaverse) and looking for a small cap company to help you participation in it, then look no further than Liquid Avatar.
Watch this powerful interview with CEO David Lucatch.
Posted by AGORACOM
at 4:35 PM on Wednesday, January 5th, 2022
BRAND NEW LISTING – DEC 21
The World Needs Copper: Global Copper Consumption Outstripping Supply
“A new energy vehicle (EV) needs 80kg of Copper compared with 23kg in an internal combustion engine vehicle” Kitco
Demand for Copper is projected to rise by 5% yearly, outstripping supply which is projected to increase by 2.3% yearly
This is why brand new Fabled Copper’s mandate is to explore and define high level and high-grade copper resources in Northern BC. ( which also happens to be a tier one exploration jurisdiction). Their main focus is the Muskwa property with a high grade mining history containing a minimum of 22 documented copper occurrences of which 4 are defined deposits with historical reserves and resources.
Fabled is taking an aggressive exploration approach and are already outlining a drill program for the 22 field season.
Here are some of the documented copper occurrences in 3 separate claim blocks (Neil, Toro, Bronson) and you can see why Fabled is intent on taking a aggressive approach to exploration and development. The project boast highgrade copper and lots of it.
Neil: 10 Copper occurrences with the Neil vein 19 metres wide, visible for more than 1,000 metres vertically & has assayed 10.2% copper over 3.0 metres
Davis-Keays: Historical Indicated reserve *of 3.7 million tons at 2.5% Copper cut-off grade or an estimated 1.4million tons at 3.42% Copper
Toro-Churchill: – sampling returned 8.8% copper over a width of 19 meters and strike length of 133 meters
Magnum Vein: developed and mined from 1970 to 1974 milling 549,000 tons grading 3.00 % Copper – stopped due to low copper prices
And if that doesn’t help identify the discovery opportunity, have a look at the combined experience amongst the management team, over 200 years’ combined exploration experience; and with that comes knowledge, lots of it. They are using their experience with cutting edge technologies to exploit the significant exploration upside. The use of drones has been prevalent throughout the 2021 exploration program and combined with the use of LIDAR and modern geophysics, the team plans on using the information gained to lead a very aggressive 2022 program that will include drilling.
At a time when Copper is breaking out and trending within the 4.20 to 4.80 price range; up over 100% since early 2020, Fabled shareholders received a generous Christmas present from Peter Hawley, President & CEO as the company embarks on delivering the Copper supply needed for the needs of tomorrow.
Sit back and enjoy this fantastic video as Peter walks us through the next emerging Copper growth story of 2022 and beyond.
